FDA
-
-
-
-
-
-
-
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
-
-
-
-
-
-
-
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
-
-
-
-
-
-
-
Shuttle Pharmaceuticals (SHPH) Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
-
-
-
-
-
-
-
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
-
-
-
-
-
-
-
Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
-
-
323,630 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

